These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 31850312)

  • 1. The Structural Biology of Galectin-Ligand Recognition: Current Advances in Modeling Tools, Protein Engineering, and Inhibitor Design.
    Modenutti CP; Capurro JIB; Di Lella S; Martí MA
    Front Chem; 2019; 7():823. PubMed ID: 31850312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of selected blood and immune cell responses to carbohydrate-dependent surface binding of proto- and chimera-type galectins.
    Timoshenko AV; Gorudko IV; Maslakova OV; André S; Kuwabara I; Liu FT; Kaltner H; Gabius HJ
    Mol Cell Biochem; 2003 Aug; 250(1-2):139-49. PubMed ID: 12962152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis for the recognition of carbohydrates by human galectin-7.
    Leonidas DD; Vatzaki EH; Vorum H; Celis JE; Madsen P; Acharya KR
    Biochemistry; 1998 Oct; 37(40):13930-40. PubMed ID: 9760227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for subsites in the galectins involved in sugar binding at the nonreducing end of the central galactose of oligosaccharide ligands: sequence analysis, homology modeling and mutagenesis studies of hamster galectin-3.
    Henrick K; Bawumia S; Barboni EA; Mehul B; Hughes RC
    Glycobiology; 1998 Jan; 8(1):45-57. PubMed ID: 9451013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycomimetic inhibitors of tandem-repeat galectins: Simple and efficient.
    Vrbata D; Červený J; Kulik N; Hovorková M; Balogová S; Vlachová M; Pelantová H; Křen V; Bojarová P
    Bioorg Chem; 2024 Apr; 145():107231. PubMed ID: 38394919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the Molecular Interactions of Symmetrical and Unsymmetrical Selenoglycosides with Human Galectin-1 and Galectin-3.
    Pirone L; Nieto-Fabregat F; Di Gaetano S; Capasso D; Russo R; Traboni S; Molinaro A; Iadonisi A; Saviano M; Marchetti R; Silipo A; Pedone E
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure of full-length Toxascaris leonina galectin with two carbohydrate-recognition domains.
    Jeong MS; Hwang HG; Yu HS; Jang SB
    Acta Crystallogr D Biol Crystallogr; 2013 Feb; 69(Pt 2):168-75. PubMed ID: 23385453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An integrated computational analysis of the structure, dynamics, and ligand binding interactions of the human galectin network.
    Guardia CM; Gauto DF; Di Lella S; Rabinovich GA; Martí MA; Estrin DA
    J Chem Inf Model; 2011 Aug; 51(8):1918-30. PubMed ID: 21702482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural analysis of the human galectin-9 N-terminal carbohydrate recognition domain reveals unexpected properties that differ from the mouse orthologue.
    Nagae M; Nishi N; Nakamura-Tsuruta S; Hirabayashi J; Wakatsuki S; Kato R
    J Mol Biol; 2008 Jan; 375(1):119-35. PubMed ID: 18005988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galectins-1 and -3 and their ligands in tumor biology. Non-uniform properties in cell-surface presentation and modulation of adhesion to matrix glycoproteins for various tumor cell lines, in biodistribution of free and liposome-bound galectins and in their expression by breast and colorectal carcinomas with/without metastatic propensity.
    André S; Kojima S; Yamazaki N; Fink C; Kaltner H; Kayser K; Gabius HJ
    J Cancer Res Clin Oncol; 1999; 125(8-9):461-74. PubMed ID: 10480338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissecting the Structure-Activity Relationship of Galectin-Ligand Interactions.
    Chan YC; Lin HY; Tu Z; Kuo YH; Hsu SD; Lin CH
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thermodynamic binding studies of bivalent oligosaccharides to galectin-1, galectin-3, and the carbohydrate recognition domain of galectin-3.
    Ahmad N; Gabius HJ; Sabesan S; Oscarson S; Brewer CF
    Glycobiology; 2004 Sep; 14(9):817-25. PubMed ID: 15148296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Placental galectins: a subfamily of galectins lose the ability to bind β-galactosides with new structural features†.
    Pei X; Zhu J; Wang Y; Zhang F; He Y; Li Y; Si Y
    Biol Reprod; 2023 Dec; 109(6):799-811. PubMed ID: 37672213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-carbohydrate strategies to inhibit lectin proteins with special emphasis on galectins.
    Sethi A; Sanam S; Alvala M
    Eur J Med Chem; 2021 Oct; 222():113561. PubMed ID: 34146913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural analysis of the recognition mechanism of poly-N-acetyllactosamine by the human galectin-9 N-terminal carbohydrate recognition domain.
    Nagae M; Nishi N; Murata T; Usui T; Nakamura T; Wakatsuki S; Kato R
    Glycobiology; 2009 Feb; 19(2):112-7. PubMed ID: 18977853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Galβ-(syn)-gauche configuration is required for galectin-recognition disaccharides.
    Iwaki J; Tateno H; Nishi N; Minamisawa T; Nakamura-Tsuruta S; Itakura Y; Kominami J; Urashima T; Nakamura T; Hirabayashi J
    Biochim Biophys Acta; 2011 Jul; 1810(7):643-51. PubMed ID: 21514365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. X-ray structure of a protease-resistant mutant form of human galectin-8 with two carbohydrate recognition domains.
    Yoshida H; Yamashita S; Teraoka M; Itoh A; Nakakita S; Nishi N; Kamitori S
    FEBS J; 2012 Oct; 279(20):3937-51. PubMed ID: 22913484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorescence polarization as an analytical tool to evaluate galectin-ligand interactions.
    Sörme P; Kahl-Knutsson B; Huflejt M; Nilsson UJ; Leffler H
    Anal Biochem; 2004 Nov; 334(1):36-47. PubMed ID: 15464951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lactulose as a novel template for anticancer drug development targeting galectins.
    Kishor C; Ross RL; Blanchard H
    Chem Biol Drug Des; 2018 Oct; 92(4):1801-1808. PubMed ID: 29888844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galectin-3 inhibitors: a patent review (2008-present).
    Blanchard H; Yu X; Collins PM; Bum-Erdene K
    Expert Opin Ther Pat; 2014 Oct; 24(10):1053-65. PubMed ID: 25109359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.